ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.  Key topics include  Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET  Clinical implications of the EMERALD subgroup analyses  Review of elacestrant's safety profile       Clinical takeaways  Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer  The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N  Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors  These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression    This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.    This video was developed by https://cor2ed.com/      Published March 2025 

There are no comments yet.

Please log in to write the first comment.